Cite
Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers
MLA
Kui-Jin Kim, et al. “Cetuximab Resistance Induced by Hepatocyte Growth Factor Is Overcome by MET Inhibition in KRAS, NRAS, and BRAF Wild-Type Colorectal Cancers.” Journal of Cancer Research and Clinical Oncology, vol. 148, Dec. 2021, pp. 2995–3005. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c70a62d8a3145d10f53940b1ad0da76f&authtype=sso&custid=ns315887.
APA
Kui-Jin Kim, Soo Mee Bang, Yu Jung Kim, Milang Nam, Ji Won Kim, Jin Won Kim, Ji Hea Sung, Ju Hyun Lee, Hyejoo Park, Jee Hyun Kim, Koung Jin Suh, Sang-A Kim, Eun Hee Jung, Ji Yun Lee, Jong Seok Lee, Keun-Wook Lee, Jeong Ok Lee, & Se Hyun Kim. (2021). Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers. Journal of Cancer Research and Clinical Oncology, 148, 2995–3005.
Chicago
Kui-Jin Kim, Soo Mee Bang, Yu Jung Kim, Milang Nam, Ji Won Kim, Jin Won Kim, Ji Hea Sung, et al. 2021. “Cetuximab Resistance Induced by Hepatocyte Growth Factor Is Overcome by MET Inhibition in KRAS, NRAS, and BRAF Wild-Type Colorectal Cancers.” Journal of Cancer Research and Clinical Oncology 148 (December): 2995–3005. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c70a62d8a3145d10f53940b1ad0da76f&authtype=sso&custid=ns315887.